← 프로그램

🔵 전립선암

59개 프로그램

Data Tier 보기전체 목록PD-1 비교Data Tier TOP 4갱신 필요

Data Tier

ADC · Antibody · CGT를 FDA 승인, ORR·PASI·ACR·BCVA, 임상 등록 규모, Phase 3, 조회수 등 공개 데이터로 복합 점수화합니다. S–C 티어와 가점 요인은 규칙 기반(Data Tier)이며 LLM이 아닙니다.

상위 3개 비교RSS 구독차세대 추천

Modality

전체 (3)ADC (87)Antibody (170)CGT (23)

질환

전체🎗️ HER2+ 유방암 (50)🫁 폐암 (NSCLC) (27)🦴 다발성 골수종 (20)🩸 림프종 (46)🔬 대장·직결장암 (31)🫃 위암 (12)☀️ 흑색종 (6)🔵 전립선암 (3)💧 방광·요로상피 (9)🌸 난소암 (28)🧬 혈액암 (AML/ALL) (62)📊 고형암 (전체) (73)👁️ 황반변성·망막 (5)🤲 류마티스관절염 (4)🧴 건선 (12)🍽️ IBD (크론·대장) (8)🩹 아토피·피부염 (8)💨 천식 (3)🛡️ 자가면역·염증성 (9)

타깃

전체HER2 (17)PD-1 / PD-L1 (8)BCMA (3)CD19 (5)EGFR (1)VEGF (3)TNF-α (4)IL-12 / IL-23 (2)IL-4R (2)IL-13 (1)IL-17A (3)

S Tier1개

승인·효능·임상 규모·관심도 종합 상위

Tier프로그램Modality점수가점 요인요약분석
SAA (Abiraterone acetate)
Janssen Research & Development,… · Metastatic Castration-sensitive Prostate
CGT72Phase 3ORR 57.1%PFS 데이터OS 보고임상 77건CGT — Phase 3 · ORR 57.1% · PFS 데이터CGT Phase 3로 후기 임상을 진행 중입니다. 보고된 ORR 57.1%는 동일 Metastatic Castration-sensitive Prostate·Metastatic Castration-se군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 23,310명 규모.
S72점
AA

CGT · Janssen Research & Development,… · Metastatic Castration-sensitive Prostate

CGT — Phase 3 · ORR 57.1% · PFS 데이터

Phase 3 · ORR 57.1% · PFS 데이터 · OS 보고

CGT Phase 3로 후기 임상을 진행 중입니다. 보고된 ORR 57.1%는 동일 Metastatic Castration-sensitive Prostate·Metastatic Castration-se군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 23,310명 규모.

B Tier1개

중간 수준 — 확장 데이터 또는 초기 단계

Tier프로그램Modality점수가점 요인요약분석
BADT (androgen deprivation therapy)
Istituto Clinico Humanitas · Oligorecurrent and Oligoprogressive Pros
Antibody34PFS 데이터임상 72건등록 19,999명Phase 3 15건참고문헌 풍부Antibody — PFS 데이터 · 임상 72건 · 등록 19,999명Antibody 초기·전임상 단계로 데이터가 제한적입니다. 임상 72건으로 개발 깊이가 두드러집니다. 등록 환자 합산 약 19,999명 규모.
B34점
ADT

Antibody · Istituto Clinico Humanitas · Oligorecurrent and Oligoprogressive Pros

Antibody — PFS 데이터 · 임상 72건 · 등록 19,999명

PFS 데이터 · 임상 72건 · 등록 19,999명 · Phase 3 15건

Antibody 초기·전임상 단계로 데이터가 제한적입니다. 임상 72건으로 개발 깊이가 두드러집니다. 등록 환자 합산 약 19,999명 규모.

C Tier1개

초기/제한적 데이터 — 추적 관찰

Tier프로그램Modality점수가점 요인요약분석
CCytochrome P450 (CYP) Cocktail
Amgen · Metastatic Castration-resistant Prostate
Antibody12임상 104건등록 11,328명참고문헌 풍부개발 중단Antibody — 임상 104건 · 등록 11,328명 · 참고문헌 풍부Antibody 초기·전임상 단계로 데이터가 제한적입니다. 임상 104건으로 개발 깊이가 두드러집니다. 등록 환자 합산 약 11,328명 규모.
C12점
Cytochrome P450 (CYP) Cocktail

Antibody · Amgen · Metastatic Castration-resistant Prostate

Antibody — 임상 104건 · 등록 11,328명 · 참고문헌 풍부

임상 104건 · 등록 11,328명 · 참고문헌 풍부 · 개발 중단

Antibody 초기·전임상 단계로 데이터가 제한적입니다. 임상 104건으로 개발 깊이가 두드러집니다. 등록 환자 합산 약 11,328명 규모.

프로그램 (59)

CGTABiologicJanssen Research & Development,…Phase 3

AA (Abiraterone acetate, Abiraterone acetate (AA))

Metastatic Castration-sensitive Prostate Cancer · Metastatic Castration-sensitive Prostate

#MetastaticCastration-sensitivePr#CGT#Phase3#인기#세포유전치료+3
효능 ORR 57.1%임상시험 77상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab & Ipilimumab)

Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 61.3%임상시험 70상태 ACTIVE
ADCBiologicJanssen Research & Development,…Phase 1

Abiraterone acetate (Abiraterone acetate)

Metastatic Prostate Cancer · Metastatic Prostate Cancer

#MetastaticProstateCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 46%임상시험 67상태 RECRUITING
AntibodyAstraZenecaPhase 2

durvalumab (Imfinzi, durvalumab and tremelimumab)

Prostate Cancer · HCC

#HCC#Antibody#Phase2#인기#항체+5
효능 ORR 48%임상시험 63상태 ACTIVE
ADCBiologicIgenomixPhase 2

RNA analysis (RNA analysis)

Prostate Cancer · Adult Lymphocyte Depletion Hodgkin Lymph

#AdultLymphocyteDepletionHodgkinL#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 18%임상시험 62상태 ACTIVE
ADCBiologicCanadian Cancer Trials Groupderuxtecan (T-DXd) showed a…Phase 2

darolutamide (darolutamide)

Prostate Cancer · Genitourinary Cancers

#GenitourinaryCancers#ADC#Phase2#인기#항체약물접합체+4
임상시험 60상태 RECRUITING
CGTBiologicImmunityBio, Inc.sPhase 2

Activated NK Cells (M-CENK, M-CENK (Activated NK Cells))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#인기#세포유전치료+4
임상시험 59상태 DISCONTINUED
CGTBiologicCalimmune, Inc.Phase 1

Gene Modified T Cells (Gene Modified T Cells)

Prostate Cancer · Prostate Cancer

#ProstateCancer#CGT#Phase1#인기#세포유전치료+4
효능 ORR 92.9%임상시험 58상태 DISCONTINUED
ADCBiologicJanssen Research & Development,…Phase 1

Apalutamide (Apalutamide)

Prostatic Neoplasms · Metastatic Prostate Cancer

#MetastaticProstateCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 2.6%임상시험 58상태 RECRUITING
ADCBiologicAstraZenecaDM1 in Oatp1a/b -/- was 1Phase 2

Cabazitaxel (Cabazitaxel)

Progressive Metastatic Castrate-Resistant Prostate Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 57.7%임상시험 57상태 DISCONTINUED
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab monotherapy)

Advanced Metastatic Cancer; Advanced Prostate Cancer · Genitourinary Cancers

#GenitourinaryCancers#Antibody#Phase2#인기#항체+5
효능 ORR 59%임상시험 57상태 RECRUITING
CGTBiologicImmunityBio, Inc.vedotin (BT8009) and dual-A…Phase 2

IL-15 Superagonist (N-803, N-803 (IL-15 Superagonist))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 80%임상시험 57상태 DISCONTINUED
ADCBiologicEpizyme, Inc.Phase 2

Abiraterone + prednisone (Abiraterone + prednisone)

Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer · mCRPC

#mCRPC#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 46%임상시험 56상태 RECRUITING
ADCBiologicFortis Therapeutics, Inc.Phase 2

FOR46 (FOR46)

Multiple Myeloma; Multiple Myeloma in Relapse · Prostate Cancer Metastatic

#ProstateCancerMetastatic#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 51.5%임상시험 55상태 RECRUITING
AntibodyTracon Pharmaceuticals Inc.Phase 2

Androgen receptor inhibitor (Androgen receptor inhibitor)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+4
임상시험 54상태 RECRUITING
Antibody3D Medicines (Sichuan) Co., Ltd.Phase 2

Envafolimab (Envafolimab)

Prostate Cancer; CDK12 Gene Mutation · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
임상시험 52상태 RECRUITING
AntibodyRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 55.6%임상시험 51상태 ACTIVE
ADCBiologicCanadian Cancer Trials Groupvedotin, a monoclonal antib…Phase 2

Adavosertib (Adavosertib)

Prostate Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 66.7%임상시험 45상태 RECRUITING
ADCBiologicCanadian Cancer Trials GroupPhase 2

Savolitinib (Savolitinib)

Prostate Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57.1%임상시험 41상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Prostate Cancer; Prostatic Neoplasms · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 18상태 RECRUITING
ADCBiologicstaleCelgenePhase 1

Valemetostat (Valemetostat)

Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 43.7%임상시험 15상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#항체#면역항체+4
임상시험 5상태 DISCONTINUED
ADCBiologicstaleTelix Pharmaceuticals (Innovati…Phase 3

177Lu-TLX591 (177Lu-TLX591)

Metastatic Castration-resistant Prostate Cancer · Metastatic Castration-resistant Prostate

#MetastaticCastration-resistantPr#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleTelix Pharmaceuticals (Innovati…Phase 1

177Lu-DOTA-TLX591 (177Lu-DOTA-TLX591)

Metastatic Prostate Cancer · Metastatic Prostate Cancer

#MetastaticProstateCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 ACTIVE
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR-PSMA T cells (4SCAR-PSMA T cells)

PSMA Positive Tumors or Tumor Tissues · PSMA

#PSMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 4상태 ACTIVE
ADCBiologicstaleBioNTech SEPhase 3

BNT324 (BNT324)

Advanced Lung Cancer · Metastatic Castration-resistant Prostate

#MetastaticCastration-resistantPr#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
CGTBiologicstaleImmunityBio, Inc.Phase 2

PSA-based Oncolytic Virus (ETBX-071, ETBX-071 (PSA-based Oncolytic Virus))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 0%임상시험 3상태 DISCONTINUED
ADCBiologicstaleRobert Flavell, MD, PhDPhase 1

89Zr-DFO-YS5 (89Zr-DFO-YS5)

Prostate Cancer; Metastatic Castration-resistant Prostate Cancer · Prostate Cancer

#ProstateCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleJanssen Research & Development,…Phase 1

ARX517 (ARX517)

Metastatic Prostate Cancer · Metastatic Prostate Cancer

#MetastaticProstateCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 RECRUITING
ADCBiologicstaleDavid OhPhase 2

Etrumadenant (Etrumadenant)

Prostate Adenocarcinoma; Prostate Cancer · Prostatic Neoplasms, Castration-Resistan

#ProstaticNeoplasmsCastration-Res#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 2상태 ACTIVE

1 / 2 페이지

← 이전다음 →